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Abstract
Liver development is a sequential array of distinct biological events. Each step of differentiation is regulated by intrinsically programmed
mechanisms as well as by extracellular signals. The establishment of cell culture systems that recapitulate each stage of liver development has
led to the identification of several extracellular signals that affect hepatocytic differentiation. Furthermore, studies on genetically engineered
animals, especially knockout and transgenic mice, have highlighted a number of molecules essential for liver development. By applying
primary culture techniques to analyses of mutant mice, it is now possible to link extracellular signals to intracellular pathways that provoke
cellular responses of differentiation. Improvement in gene transfer technology utilizing viral vectors has further expanded the molecular
analysis of liver development. In this review article, we summarize recent advances and attempt to describe the molecular basis of liver
development from beginning to end as a sequential event.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The process of liver development can be divided into
several distinct stages based on molecular and functional
properties (Fig. 1). The initial event in the development is
commitment (also referred to as specification) of the foregut
endoderm to the hepatic lineage [1,2]. This is characterized
by the expression of two of the liver-specific markers,
albumin (Alb) and alpha feto-protein (AFP), which are
detected as early as embryonic day 8–9 (E8–9; 6–8
somites stage) in the mouse system. Hepatic cells at this
stage possess the potential to differentiate into both paren-
chymal hepatocytes and bile duct epithelial cells [3]. A
small number of such hepatic progenitors or hepatic stem
cells are believed to remain undifferentiated throughout
development and reside even in the adult liver [4], although
their precise characteristics and physiological significance
have not been clearly documented.
At around E10–11, hematopoietic stem cells originating
from the extrahepatic organ (aorta–gonads–mesonephros
region; AGM region) colonize the fetal liver and expand
their mass and lineage diversity [5,6]. Hepatic progenitors
participate in creating the hematopoietic microenvironment
in concert with other stromal cells to promote embryonic
hematopoiesis [7]. Along with the maturation of bone
marrow and spleen around birth, hematopoiesis in the liver
declines and hematopoietic stem cells migrate from the liver
to these organs responsible for adult-type hematopoiesis. On
the other hand, hepatic cells up-regulate the expression of
numerous genes relating to the functions of mature liver in
order to achieve their own metabolism after birth [8,9].
Therefore, liver development at around birth is more like a
functional switch from a hematopoietic microenvironment
to a metabolic organ than a simple maturation process.
Throughout the process of development, hepatic cells
continuously proliferate partly, if not entirely, through an
autocrine mechanism [10]. However, the growth of cells
gradually slows and is eventually arrested during postnatal
development. Thereafter, hepatocytes no longer proliferate
autonomously and their proliferation requires exogenously
provided growth factors such as epidermal growth factor
(EGF) and hepatocyte growth factor (HGF). Concurrently, a
set of genes, including those involved in amino acid
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metabolism and detoxification, are up-regulated to consti-
tute fully differentiated adult hepatocytes (terminal differ-
entiation) [8]. In addition to the differentiation at the single
cell level, hepatocytes and several other nonparenchymal
cells start creating the sinusoidal structure and major hepatic
vessels as well as bile ducts to organize a liver lobule that is
a basic unit of the liver tissue.
Several cell culture systems briefly described below were
shown to reproduce partial process of liver development.
Besides these in vitro systems, there is an increasing number
of knockout (KO) mice that display abnormalities in the
liver at different developmental stages. Studies have now
provided the outline of the process of liver development
from beginning to end. In this review, we summarize recent
progress in this field, primarily focusing upon the roles of
extracellular factors and their possible link with downstream
pathways.
2. Specification of the hepatocytic lineage from the
foregut endoderm
Parenchymal hepatocytes and bile duct epithelial cells
originate from foregut endodermal epithelial cells.
LeDouarin’s classic experiment utilizing chicken embryos
demonstrated that transplantation of an endodermal tissue
at the 4–6-somite stage into the precardiac mesoderm gave
rise to a tissue that morphologically resembled the hepato-
cytic organ [11]. This was the first demonstration that
interaction between endodermal and mesodermal tissues
is important for hepatic development. Zaret and his col-
leagues adapted this idea and established a tissue explant
assay in a microwell format using mouse embryos and
investigated the molecule that mediates the endoderm–
mesoderm interaction [12]. They found that while the
inductive signal from the cardiac organ was not dependent
on direct contact with the endoderm, it still required close
proximity to the endoderm [13]. In addition, the inductive
signal was apparently not mediated by a soluble factor
secreted into culture media. Based on these observations,
they searched for locally acting factors expressed in the
cardiac mesoderm at this stage and identified fibroblast
growth factor (FGF) family proteins (FGF1, 2 and 8) as
potential candidates. (Though FGFs are secreted proteins,
they often retain locally in association with extracellular
matrices such as heparin.) In contrast, FGFR-1 and FGFR-
4, receptors for these FGF species, were found to be
expressed on endodermal cells [14], suggesting that the
FGF–FGFR system is operative between endoderm and
cardiac mesoderm. They therefore stimulated endodermal
cells with either of these FGFs in the absence of the cardiac
organ and found that both FGF-1 and FGF-2 were capable
of inducing the expression of albumin mRNA at physio-
logical concentrations. Moreover, neutralizing antibodies
against FGFR-1 and FGFR-4 strongly inhibited the expres-
sion of albumin mRNA induced by the cardiac organ.
While FGF8 was unable to up-regulate albumin mRNA
expression, it seemed to have a positive effect on the
outgrowth of hepatic cells after specification. Based on
these observations, it was proposed that the FGF–FGFR
system is critical for the initial process of liver development
(Fig. 2) [14].
A more recent study from the Zaret laboratory further
extended our understanding of the initial step of hepato-
Fig. 1. Process of liver development. Hepatic cells arise from foregut endodermal cells in response to signals from neighboring mesenchymal cells. In time,
hematopoietic stem cells from the extrahepatic organ (the AGM region) colonize the fetal liver and expand their mass and lineage diversity. Along with
maturation of the liver as a metabolic organ at around birth, hematopoietic cells relocate to the bone marrow or spleen. Hepatocytes proceed to further round of
maturation process during postnatal development that accompanies termination of cell proliferation. Letters in italic are developmental marker genes often used
in the developmental biology of the liver. TAT, tyrosine amino-transferase; G6Pase, glucose-6-phosphatase (peri/postnatal hepatocyte markers); TO, tryptophan
oxygenase; P450, cytochrome P450 species (terminal differentiation markers).
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genesis [15]. Several preceding studies have suggested that
an additional signal from the septum transversum mesen-
chyme, originating from the lateral plate mesoderm, con-
tributes to the initial stage of hepatic induction as well
[11,16,17]. It was also known that a member of the
transforming growth factor beta (TGFh)/bone morphogenic
protein (BMP) family plays a critical role in tissue organo-
genesis, such as the lung and tooth, and often acts
synergistically with FGF signals [18–20]. To examine
the involvement of BMP proteins in the early stage of
hepatogenesis, several distinct approaches were utilized as
follows. First, a mouse model was used in which the LacZ
reporter gene was inserted into the BMP4 locus [15]. LacZ
reconstituted the normal BMP4 expression pattern and was
co-localized with a marker gene (Mrg1) [21] specific for
the septum transversum. In the BMP4-deficient embryos,
the liver bud failed to enlarge and albumin was not
expressed. In agreement with these observations, suppres-
sion of BMP signaling by a natural antagonist, noggin
(Xnoggin) [22], inhibited albumin induction in the explant
assay. Moreover, the FGF-induced albumin expression in
endodermal cells was also inhibited by Xnoggin, suggest-
ing that a BMP signal is essential for FGF-mediated
induction of liver development. It was also shown that a
signal from BMPs is insufficient for induction of hepatic
differentiation. The expression patterns of TGFh/BMP
proteins during development and the activities of these
proteins to restore albumin expression in the presence of
Xnoggin indicated that BMP4 and BMP2 are likely to be
responsible for hepatic induction in vivo (Fig. 2). Interest-
ingly, cells, which are inhibited by Xnoggin to become the
hepatic lineage cells, express a marker gene for the pan-
creas (Pdx) that also originates from the foregut endoderm.
Thus, the systems of FGF and BMP appear to coopera-
tively control the bi-directional differentiation of endoder-
mal cells [15].
The downstream pathway(s) of FGFs and BMPs respon-
sible for induction of hepatic differentiation is unclear.
While the FGF family generates inductive signals for many
solid tissues [23,24], they are potent growth factors for
many cell types as well [25]. As both cell proliferation and
differentiation signals are transmitted through the same FGF
receptor, the specificity of differentiation signals could be
generated through the BMP receptors. The albumin gene
enhancer has binding sites for liver-enriched transcription
factors such as hepatic nuclear factor (HNF) 3, GATA4 and
CAAT-enhancer binding proteins (C/EBP) [26–28], and
GATA4 expression was found to be reduced in liver
explants derived from BMP4-deficient mice [15]. Thus,
BMP4-regulated GATA4 expression could be a key deter-
minant to become hepatic cells or to proliferate in response
to FGF. GATA factors are known to regulate the tran-
scription of other liver-enriched factors such as HNF4a in
hepatic cells [29]. Therefore, it is likely that the network of
these transcription factors regulated by BMPs contributes to
endodermal patterning by allowing liver-specific genes to be
expressed in response to FGFs, and consequently prevents
induction of the pancreas.
Fig. 2. A possible model for the mechanism of early hepatic specification. Generation of the hepatic primordium from the foregut endoderm requires at least
two different signals, i.e., BMP and FGF family proteins. These proteins are produced by mesenchymal cells in septum transversum and cardiac organ,
respectively. Although intracellular signaling mechanisms are yet unclear, several lines of evidence indicated that GATA and HNF3 transcription factors play
critical roles in inducing liver-specific or enriched proteins including albumin and HNF4.
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3. From the fetal to neonatal stage
After endodermal cells commit to the hepatic cell line-
age, they undergo maturation programs during which they
acquire various specific functions necessary for the metab-
olism after birth. Along with this process, hepatic progen-
itors differentiate into either hepatocytes or bile duct cells.
Embryonic hepatic cells should not simply be considered as
immature nonfunctional cells, because fetal liver is the
major hematopoietic tissue in the late gestation to neonatal
stage [30]. Therefore, liver development from the fetus to
neonate is a functional switch rather than a simple matura-
tion, although the precise mechanism regulating this process
had not been characterized until recently.
Extensive studies by Darlington and colleagues on C/
EBPa KO mice have provided a molecular basis of liver
development at this stage [31–33]. C/EBPa is a transcription
factor expressed in the liver that binds to the CAAT/enhancer
sequences of the 5V-upstream region and activates target
genes in the liver [26]. C/EBPa KO mice die immediately
after birth, partly if not entirely, because of hypoglycemia,
and administration of glucose extends their survival for
several days [31]. Although the structure of the liver tissue
was apparently normal in C/EBPa KO mice, the storage
levels of hepatic glycogen and lipids were extremely low in
comparison with those in control mice, indicating that C/
EBPa is essential for functional maturation of hepatocytes. It
has also been shown that C/EBPa is involved in the down-
regulation of cell growth [34]. In C/EBPa KO mice, the
expression of growth-related genes (PCNA, c-jun and c-myc)
was up-regulated, while molecules involved in cell cycle
arrest such as p21 were down-regulated [32]. Consistent with
these observations, the number of cells remaining in a growth
phase increased in KO livers at the perinatal stage. Thus, C/
EBPa plays dual roles during liver development, i.e., in
hepatic maturation and cell cycle regulation.
We previously established a primary culture system for
murine fetal hepatocytes derived from the liver at the mid-
embryonic stage (E14.5) [35,36]. The major cell popula-
tion in this culture is parenchymal hepatocytes, judging
from their epithelial morphology, expression of liver-spe-
cific marker proteins (albumin and AFP) and autonomous
proliferation. In addition, cells do not yet express marker
proteins in neonatal and adult livers. We used this system
to screen extracellular factors that promote hepatocytic
development and identified Oncostatin M (OSM), an
interleukin (IL) 6-related cytokine, and glucocorticoid as
powerful inducers of liver development [35]. OSM not
only stimulates expression of hepatic differentiation
markers but also induces morphological changes, up-reg-
ulation of multiple liver-specific functions, ammonia clear-
ance, lipid synthesis, glycogen synthesis, detoxification,
[35,37] and enhancement of homophilic cell adhesion [38],
all of which are characteristics of postnatal liver cells. This
was not a consequence of the inhibition of cell prolifer-
ation, because TGFh, a potent inhibitor of fetal hepatocyte
proliferation, did not up-regulate the expression of differ-
entiation markers [35]. Stimulation with glucocorticoid
alone was capable of inducing most of the cellular
responses of differentiation, however, to a far lesser extent
than the combination with OSM. In contrast, OSM alone
failed to induce differentiated phenotypes of the liver. This
implies that glucocorticoid is an essential trigger for
hepatic maturation, while OSM enhances the effect of
glucocorticoid. In the developing liver, OSM is expressed
in CD45+ hematopoietic cells, but not in hepatocytes [35].
These results suggest that OSM is a paracrine mediator of
liver development, although more detailed analysis includ-
ing those on OSM and OSMR KO mice is necessary to
further define the role for OSM in vivo. Shen et al. [39]
demonstrated that embryonic pancreatic islet cells trans-
differentiated into cells of the hepatocytic lineage in vitro
when stimulated with glucocorticoid. Interestingly, OSM
strongly potentiated the expression of albumin induced by
glucocorticoid in these cells. This suggests that OSM acts
on multiple types of cells and enhances cell differentiation
toward the hepatocytic lineage, although its physiological
relevance in vivo remains to be addressed.
OSM manifests its biological activity by activating down-
stream intracellular signaling pathways through a specific
receptor complex (OSM receptor; OSMR) composed of the
OSM-specific subunit (OSMR h chain) and a common signal
transducer, gp130 [40,41]. Two major pathways are activated
through OSMR, the signal transducer and activator of tran-
scription (STAT) 3 and Ras pathways, and each of them was
shown to be involved in many different biological responses
in a cell type-dependent manner [42,43]. Studies using a
retrovirus-mediated gene transfer technique revealed that the
STAT3 pathway is essential for the expression of hepatic
differentiation markers induced by OSM [44]. Since 5V-
regulatory sequences of hepatic differentiation marker genes
often contain STAT3-binding sequences [45,46], it is likely
that STAT3 directly regulates transcription. On the contrary,
however, Leu et al. [46] demonstrated that regulation by
STAT3 of HNF1-dependent transcription in hepatic cells
does not depend on the DNA-binding domain of STAT3.
Therefore, it is also possible that STAT3 regulates gene
expression indirectly through regulation of other transcrip-
tion factors presumably through protein–protein interaction.
On the other hand, the Ras pathway appears to have an
opposing effect on gene activation, since the blockade of
this pathway either by dominant negative Ras or by an
inhibitor for its downstream target, MEK, augmented
expression of hepatic differentiation markers.
Our group recently highlighted the specific role for K-
Ras in regulation of homophilic adhesion during OSM-
induced hepatic development [38]. In response to OSM,
fetal hepatic cells in culture form cadherin-dependent
adherence junction. Since this effect was blocked by
dominant-negative Ras, we examined cells from KO mice
deficient for K-Ras, H-Ras and/or N-Ras allele. Interest-
ingly, only K-Ras deficiency abolished OSM-induced for-
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mation of adherence junction without an apparent effect on
expression of hepatic differentiation markers. Moreover,
ectopic expression of K-Ras cDNA restored the signal;
therefore, it is likely that K-Ras mediates the signal from
OSMR that leads to homophilic adhesion. Since K-Ras
KO mice die at E14 prior to the formation of adherence
junctions in vivo [47,48], it is impossible to address at this
moment how much this function of K-Ras is required for
liver development. However, our data provide a good
example that a primary culture system can be utilized to
analyze the consequence of gene knockout even if
embryos die in utero.
4. Possible factors involved in hepatic maturation
OSM is not the only factor that induces hepatocytic
development at this stage. HGF is known to be involved in
regeneration of the liver after hepatic injury. Disruption of the
HGF allele resulted in liver abnormality and embryonic
lethality at around E14 [49,50]. Importantly, in utero injection
of HGF ameliorated the liver defects and rescued the embryos
[51], suggesting that HGF is also involved in liver develop-
ment. Consistent with these results, stimulation of fetal
hepatic cells in primary culture with a physiological concen-
tration of HGF up-regulated the expression of hepatic differ-
entiation markers in the presence of glucocorticoid, although
to a lesser extent in comparison with OSM [52]. Interestingly,
the induction of differentiation markers by HGF was not
inhibited by dominant negative STAT3, even though STAT3
is activated by HGF in these cells. This suggests that there is
an alternative intracellular pathway regulating hepatocytic
development at least in vitro. However, it is again contro-
versial how this growth-promoting factor transduces differ-
entiation signals through the same receptor complex.
TGFh is also a possible soluble regulator of liver devel-
opment, although TGFh failed to induce differentiation
markers in fetal hepatic cells in vitro. However, hepatic
cells at a later stage (E18-19) were induced to express these
genes upon TGFh stimulation, implicating TGFh in hepatic
development as well [53]. Since TGFh (or its family
members such as BMPs and activins) inhibits hepatocyte
proliferation that occurs late-fetal to postnatal development,
TGFh may take more important role in cell cycle inhibition
than in maturation at this stage.
Another inductive signal of hepatic development is
apparently generated through cell–cell adhesion, since hep-
atocytes are induced to exhibit many characteristics of the
differentiated liver, when they are cultured at high cell
densities in the presence of glucocorticoid [37]. Since
hepatocytes are able to differentiate to some extent in
gp130-deficient mice in high-density cultures [37], it is
not due to endogenously produced OSM or other IL-6-
related factors. Thus far, a molecular basis of gp130-
independent differentiation remains unclear; however, gene
expression induced by OSM or by high-density culture was
abrogated by an inhibitor of protein tyrosine phosphatases
(PTPs) (Nakano and Miyajima, unpublished). It is therefore
possible that a certain PTP molecule plays an essential role
in hepatic development.
5. Fetal liver hematopoiesis
Transient hematopoiesis occurs in the fetal liver during
embryogenesis and has a close interaction with liver cell
development [54]. While hepatic cells are believed to
participate in creating the hematopoietic microenvironment,
mechanisms of embryonic hematopoiesis have been studied
solely by researchers in the hematology field. Such studies
include the establishment of a number of cell lines from fetal
livers capable of supporting hematopoiesis [30,55]. While
most of these stromal cells are believed to originate from
mesenchymal cells, several lines of evidence indicate that
parenchymal hepatocytes participate in the regulation of
hematopoiesis as well [7,56,57]. We utilized primary fetal
hepatic cells as hematopoietic stroma and investigated how
embryonic hematopoiesis is regulated along with the liver
development [36,58]. Co-culture of hematopoietic stem
cells over the primary culture of fetal hepatic cells allowed
expansion of both hematopoietic stem cells and of lineage-
committed cells including myeloid, erythroid and lymphoid
cells. Of particular interest, when stromal cells (fetal hepatic
cells) were induced to differentiate by OSM and glucocorti-
coid, hematopoiesis was apparently suppressed [36,59].
Since OSM does not directly act on hematopoietic cells
except for megakaryocyte [60], OSM appeared to have
suppressed hematopoiesis by inhibiting the activity of fetal
hepatic cells to support hematopoiesis. These results thus
suggest that promotion of hepatic differentiation by OSM
not only induces maturation as a metabolic organ but also
down-regulates embryonic hematopoiesis. It is, however,
noteworthy that a fraction of hematopoietic progenitor cells
(including stem cells) generated during co-culture was not
influenced by differentiation signals. Moreover, those
immature cells were even amplified in the presence of
OSM when AGM cells were used as a source of hemato-
poietic stem cells [58]. It is therefore likely that induction of
hepatic differentiation preferentially suppresses expansion
of lineage-committed cells. As reported by Wineman et al.
[55], distinct types of stromal cells differentially contribute
to regulation of lineage-committed hematopoietic cells and
stem cells. Probably, a subpopulation of stromal cells
insensitive to OSM regulates expansion and self-renewal
of hematopoietic stem cells.
6. Multiple signals are required for terminal
differentiation
The final step of hepatic differentiation takes place
several days after birth in rodents (terminal differentia-
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tion). This process includes induction of another set of
genes relating to functions of the adult liver, such as
tryptophan oxygenase (TO) [61] and several P450 species
[62]. In addition, cellular growth and expression of
growth-related genes were either terminated or down-
regulated during terminal differentiation. Terminal differ-
entiation of hepatocytes in primary culture evidenced by
TO mRNA expression was not induced by OSM or by
high-density culture and required an additional signal(s)
generated through an extracellular matrix (ECM) to be
induced [63]. Importantly, terminal differentiation does
not occur in the absence of either one of these signals,
i.e., OSM, glucocorticoid, high-density culture and ECM.
Thus, there appears to be a highly complicated cross-talk
between intracellular signaling pathways generated by
these extracellular stimuli (Fig. 3). Since transformed
hepatomas or hepatocarcinomas often lose expression of
TO mRNA [64], analysis on regulatory mechanism of TO
gene activation is an important issue to be addressed.
7. Growth control of hepatocytes revealed by gene
targeting
A number of KO mice have been generated in the past
decade and there is a significant number of mutant mice
that show developmental defects in the liver. Fig. 4
summarizes genes whose knockout caused abnormalities
in hepatocytes during development. For example, disrup-
tion of the c-jun allele (c-jun KO) gave rise to embryonic
lethality at around E12-14 [65]. In the liver of c-jun KO
embryos, severe growth retardation and apoptosis of
hepatocytes were observed in the entire liver tissue. More-
over, analysis on chimeric mice consisting of c-jun KO
and wild-type cells revealed that ES cells lacking the c-jun
allele were unable to contribute to the liver, further
confirming that c-jun is essential for hepatocytic develop-
ment. More recently, Behrens et al. [66] reported that c-
jun deficiency also perturbs postnatal growth as well as
liver regeneration, implicating c-jun in growth regulation
of hepatocytes throughout development and tissue-repair-
ing process. The importance of the c-Jun signaling path-
way was further supported by KO mice deficient for
SEK1/MKK4, an upstream regulator for c-Jun [67]. The
phenotypes of SEK1 KO share many similarities with
those of c-jun, for example, lethality at around 12–14
and massive apoptosis of hepatocytes. In both KO lines,
no apparent defect was found in remaining hematopoietic
cells and they were able to reconstitute the full hemato-
poietic system in lethally irradiated adult mice. Accord-
ingly, both genes are likely to be implicated specifically in
hepatocytic development at this stage. A possible candi-
date for the extracellular signal that triggers this pathway
is HGF, since there are certain similarities between the
phenotypes of these KO mice [49,50]. In addition, HGF
can activate the c-Jun pathway in hepatocytes [68,69],
supporting the possibility that HGF regulates c-Jun and
SEK1 in the developing liver.
Fig. 3. Multiple distinct signals are required to promote the late stage of liver development. While development from late-fetal to neonatal stage can be
stimulated with OSM and glucocorticoid hormone, terminal differentiation of hepatocytes apparently requires signals from extracellular matrix as well as
homophilic interaction. Note that many different types of cells are involved in production of such signals.
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Another important intracellular player identified from
KO studies is NFnB, a transcription factor that stays in
the cytosol as an inactive complex with an inhibitory
protein, InB, in the absence of stimuli [70]. Upon stim-
ulation with cytokines such as tumor necrosis factor alpha
(TNF-a) and IL-1, InB is phosphorylated and released
from the NFnB–InB complex. Free NFnB translocates to
the nucleus and stimulates transcription of target genes. It
is also known that a specific protein complex in cytosol is
responsible for stimuli-dependent InB phosphorylation
(InB kinase, IKK) that leads to ubiquitin-dependent deg-
radation of InB [71]. Knockout of a subunit of NFnB
(Rel-A) or IKK (IKK-h, NEMO/IKK-g) resulted in
reduced activation of NFnB in response to TNF-a- and
of NFnB-dependent transcription [72–74]. During embry-
onic development, fetal hepatocytes suffer from massive
apoptosis and subsequent loss of tissue, leading to the
lethality at around E14. Since activation of NFnB is
known to be necessary for suppression of the TNF-a-
triggered apoptotic program [75,76], it is conceivable that
the lethality caused by KO of NFnB or its regulators was
resulted from reduced expression of genes indispensable
for hepatocyte survival at this stage. These observations
also raise a possibility that TNF-a is a principal regulator
for survival of hepatocytes during embryonic develop-
ment; however, knockout of RIP, a signal transducer for
the TNF-a receptor [77], did not cause apparent liver
abnormality. Therefore, another molecule that activates the
NFnB pathway appears to be involved in liver develop-
ment in addition to TNF-a.
Above two signaling pathways are known to be stimu-
lated during regenerative responses of the adult liver
following various hepatic injuries [78]. Thus, there seem
to be regulatory mechanisms of hepatocyte proliferation
Fig. 4. Extra- and intracellular molecules involved in hepatic development. Genes or proteins involved in various stages of liver development are shown.
Molecules with underline were identified from studies of KO mice. *The KO model that has been generated by a gene-trap technology.
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common to both liver development and liver regeneration.
Embryonic lethality of KO mice has often been an obstacle
to analyze the function of a gene of interest in later stages
of development or in adult. To avoid this problem, a
conditional targeting strategy is becoming popular in
various fields. Analysis of 5V-regulatory regions of hepatic
differentiation marker genes, such as TAT and TO (see
Fig. 1, legend), will help us not only to understand the
molecular basis of their regulation but also to generate
conditional KO mice using a regulatory region of these
genes.
8. Liver stem cells
Stem cells are defined as the cells with the self-renewing
activity and capability to generate multiple types of lineage-
committed cells. As for the hepatocytic lineage, stem cells
have to possess the ability to generate both parenchymal
hepatocytes and bile duct epithelial cells [79]. In the mouse
system, it is known that differentiation of liver stem-like
cells into these lineages takes place from around E12. Liver
stem cells or progenitors have been characterized based on
expression of albumin and a subset of cytokeratins [3]. On
the other hand, increasing evidence indicates the presence of
stem-like cells in the adult liver, namely oval cells [3].
Characterization of these stem-like cells has revealed many
common features between immature embryonic hepatic
cells and oval cells. Since transplantation of stem cells (or
equivalents) is a promising therapeutic strategy for several
liver diseases, purification procedures of them need to be
established.
Numerous hematopoietic cell surface antigens have been
identified and extensively used as lineage markers in hem-
atology. These antigens were successfully used to identify
hematopoietic stem cells as well [80]. Likewise, identifica-
tion of cell surface antigen in liver cells is beneficial for
characterization of cell types as well as purification of a cell
population by cell sorting. In fact, it was reported that the
cell population with CD45TER119c-KitCD49+ contains
hepatic stem cells [81]. Unexpectedly, cell surface antigens
such as c-Kit and CD34, expressed in hematopoietic stem
cells, are also found in immature hepatic cells [82]. In 1999,
Petersen et al. [83] demonstrated that bone-marrow trans-
plants injected into the spleen of mice with liver damage
migrated to the injured liver and expressed albumin. These
results indicate that bone-marrow cells harbor the potential
to become cells of the hepatocytic lineage. Furthermore, it
was shown that a highly enriched fraction of hematopoietic
stem cells (Linc-KithighThy-1lowSca-1+) was shown to give
rise to albumin-positive cells [84]. Hematopoietic stem cells
were also shown to become vascular endothelial, muscle,
nerve and epithelial cells [85]. The plasticity of hemato-
poietic stem cells is one of the hottest topics in the current
biology, because it may provide a means to develop novel
cell therapies for these organs including the liver [86]. On
the other hand, it remains to be investigated how much this
cell population contributes to developmental process or
regenerative responses of liver cells under physiological
circumstances.
9. Concluding remarks
During the last several years, understanding of liver
development at the molecular level has been significantly
advanced. While genetic manipulations of mice has been
a major technique for molecular dissection of solid tissue
development, in this article we would like to suggest the
use of primary culture systems for detailed molecular
analysis of genetically engineered animals. A major
advantage of primary culture derived from mutant ani-
mals is that it avoids unexpected secondary effects or
lethality owing to defects in the liver itself or in another
organs. This advantage allows us to trace the consequen-
ces of gene inactivation in a simple system. Furthermore,
by applying gene transfer techniques, it is possible to
examine functions of a gene of interest, e.g., expression
of a missing gene or its downstream targets. We believe
that a combination of these new technologies will further
extend our understanding on liver development at the
molecular level and contribute to the advancement of
‘‘Molecular Hepatology’’ in the next few years.
Besides such molecule-oriented approaches, liver stem
cells became one of major subjects for basic hepatology
as well as regenerative medicine. We presume that it does
not take a long time to characterize the cell with stem-
like activity inside a liver tissue, because of the preceding
strategy that has been successfully used for character-
ization of hematopoietic stem cells. Combination of cell
sorting techniques and differentiation assays would
undoubtedly help to uncover the characteristics of ‘‘liver
stem cells’’ as well. Yet a rather controversial issue is the
emerging concept of the cellular plasticity. It is raising
several difficult questions; for example, do all stem cells
in each tissue come from the bone marrow through blood
circulation? Or, do they have different origins in spite of
possessing similar capabilities? From the point of clinical
application of stem cells, it does not really matter where
they come from as long as they possess multi-potency.
The presence of stem-like cells in the bone marrow can
be even beneficial, since it avoids many of the political
and ethical barriers of stem cell therapy. However, as
Terada et al. [87] and Ying et al. [88] recently suggested,
cellular plasticity shown by transplantation assays could
have been a consequence of cell fusion between trans-
planted and host cells rather than trans-differentiation. In
conclusion, the field is still immature and awaits further
extensive studies from many different points of view. It is
necessary to establish in vivo assays to trace the fate of
stem/progenitor cells from different origins including the
bone marrow and fetal liver.
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